α-Galactosidase A Co-Formulation with DGJ Chaperone
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current enzyme replacement therapies for Fabry disease, such as agalsidase alfa and agalsidase beta, have limitations including slow cardiac muscle response, limited GL-3 elimination from kidney cells, and immune reactions in some patients, highlighting the need for an alternative approach to enhance α-galactosidase A enzyme activity and stability.
Innovation Solution
A co-formulation of α-galactosidase A enzyme with an Active Site-Specific Chaperone (ASSC), specifically 1-deoxygalactonojirimycin (DGJ), is administered to stabilize the enzyme, enhance its trafficking to lysosomes, and improve its metabolic function, thereby reducing substrate accumulation and inflammatory responses.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If enzyme replacement therapy is used to treat Fabry disease, then α-Gal A activity is compensated, but immune reactions occur and cardiac muscle response is slow
Solution Approach 1:
A pharmacological chaperone molecule is introduced as an intermediary that binds to mutant α-Gal A, stabilizing its structure and enabling proper trafficking to lysosomes. This mediator allows the endogenous mutant enzyme to function without introducing foreign recombinant enzymes that trigger immune reactions.
Solution Approach 2:
The treatment activates the patient's own endogenous mutant α-Gal A enzyme through pharmacological chaperone binding, allowing the body's own enzyme to perform the therapeutic function rather than relying on externally administered recombinant enzymes that cause immunogenicity.
2Reliability
If enzyme replacement therapy is administered, then substrate accumulation is reduced, but GL-3 elimination from kidney cells is limited
Solution Approach 1:
The pharmacological chaperone alters the functional parameters of mutant α-Gal A by stabilizing its three-dimensional structure, improving its catalytic efficiency and substrate affinity. This enables the enzyme to effectively clear GL-3 from kidney cells where recombinant enzyme therapy fails to achieve adequate penetration or activity.
3Reliability
If pharmacological chaperone is used to stabilize mutant enzyme, then enzyme trafficking to lysosome is improved, but enzyme stability must be maintained
Solution Approach 1:
The pharmacological chaperone acts as a molecular mediator that binds to the mutant α-Gal A enzyme, stabilizing its folded conformation and protecting it from degradation. This intermediary interaction enables proper trafficking to lysosomes while maintaining enzyme stability throughout the cellular journey.
4Reliability
If recombinant enzyme is administered intravenously, then enzyme activity is restored, but treatment complexity and frequency increase
Solution Approach 1:
The pharmacological chaperone therapy activates the patient's own endogenous enzyme production, eliminating the need for repeated intravenous administrations of complex recombinant enzymes. The oral chaperone molecule continuously supports endogenous enzyme function, simplifying the treatment regimen to daily oral dosing.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The co-formulation increases the stability and activity of α-galactosidase A, leading to improved tissue uptake and reduced GL-3 levels in heart and kidney tissues, potentially offering a more effective treatment for Fabry disease with reduced immune reactions.
Implementation Method 1
1-deoxygalactonojirimycin and its salt, 1-deoxygalactonojirimycin hydrochloride (also known by its United States Adopted_name (USAN), migalastat hydrochloride) acts as a pharmacological chaperone for mutant α-Gal A by selectively binding to the enzyme, thereby increasing its stability and helping the enzyme fold into its correct three-dimensional shape.
Data Source
AI summary
The present application provides for compositions comprising α-galactosidase A in combination with an active site-specific chaperone for the α-galactosidase A, and methods for treating Fabry disease in a subject in need thereof, that includes a method of administering to the subject such compositions. The present application also provides methods for increasing the in vitro and in vivo stability of an α-galactosidase A enzyme formulation.